查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947959

注射型HIV治療藥物市場依治療階段、通路、最終用戶、給藥頻率及年齡層別分類－全球預測，2026-2032年

Injectable HIV Medication Market by Treatment Line, Distribution Channel, End User, Dosage Frequency, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，注射用 HIV 藥物市場規模將達到 47.5 億美元，到 2026 年將達到 50 億美元，到 2032 年將達到 75.1 億美元，複合年成長率為 6.75%。

關鍵市場統計數據
基準年 2025 47.5億美元
預計年份：2026年 50億美元
預測年份 2032 75.1億美元
複合年成長率 (%) 6.75%

簡要概述長效注射抗逆轉錄病毒如何改變臨床實務模式、依從性模式和醫療保健系統物流。

注射型抗逆轉錄病毒療法已從臨床探索發展成為切實可行的臨床選擇，重塑了愛滋病毒感染者的治療策略。與每日口服給藥相比，長效製劑具有截然不同的依從性，減輕了患者的用藥負擔，並為那些難以堅持每日服藥的患者提供了一種替代方案。同時，監管部門的核准和不斷成長的真實世界臨床數據增強了醫療服務提供者對注射療法的信心，物流基礎設施也進行了相應調整，以應對冷藏保管、給藥流程和低溫運輸配送等方面的挑戰。

治療創新、服務提供方式的重新設計和物流投資如何共同重塑了注射型抗逆轉錄病毒的治療路徑

注射型HIV藥物治療領域已發生變革性轉變，主要得益於治療方法創新、病患偏好變化、給藥方式的革新。新型長效整合酶抑制劑和合併用藥方案的出現，開啟了新的臨床路徑，使給藥頻率降低，藥物動力學更易預測。因此，臨床醫師在製定治療決策時，除了傳統的療效和安全性指標外，也開始考慮治療方法的便利性和依從性等因素。

檢驗2025年美國關稅調整及其對供應鏈、採購及定價的影響

2025年美國關稅政策為注射用HIV藥物的供應鏈經理、採購主管和全球生產商帶來了新的考量。進口關稅的提高將影響成品注射劑和原料的到岸成本結構，因此需要重新評估籌資策略和庫存管理。對於營運全球供應鏈的企業而言，關稅凸顯了近岸外包、供應商多元化和合約保障措施在降低成本波動方面的重要性。

詳細的細分分析揭示了年齡層、治療方案、給藥途徑、作用機制、給藥頻率和生產者趨勢如何決定臨床和商業性結果。

細分市場洞察揭示了影響產品定位、服​​務設計和市場推廣策略的細微臨床和商業性動態。在不同年齡層別中，成人和兒童族群在臨床試驗需求、給藥方案和依從性支持需求方面存在差異。兒童藥物的採納往往落後於製劑和安全性的考量，而成人計畫則較著重於依從性和長期耐受性。治療線細分區分第一線、補救和二線應用場景。第一線治療強調安全性和便利性，補救治療需要可靠的耐受性數據以及在接受過多種藥物治療的患者中的耐受性，而二線治療則需要在療效和既往用藥史之間取得平衡。

區域評估比較了管理體制、報銷結構和醫療服務模式，這些因素導致了關鍵區域在採納率方面的差異

三大區域的區域特徵差異顯著，進而影響監管路徑、報銷環境和分銷挑戰。在美洲，成熟的監管體系和完善的愛滋病治療網路加速了臨床試驗的開展和臨床醫生的熟悉程度，而與支付方的談判以及公私合營則推動了藥物清單編制和准入計劃的精細化。該地區通常在產生真實世界證據和快速將新的給藥模式整合到臨床實踐中方面發揮主導作用。

策略競爭概覽：創新領導者和區域製造商如何運用配方、分銷和夥伴關係策略來擴大注射療法的可及性

注射型HIV藥物的競爭格局呈現大規模綜合製藥公司和專注於製劑技術、物流和病患支援的專業製藥公司並存的局面。領先的生物製藥公司已在長效製劑的研發、臨床試驗和真實世界證據方面投入巨資，以建立臨床醫生的信任並促進與支付方的溝通。這些公司通常擁有全面的患者支援解決方案、成熟的分銷網路和全球監管方面的專業知識，使其能夠協調複雜的產品上市流程，並在多個臨床試驗點開展大規模給藥項目。

製造商、醫療服務提供者和支付方應重點關注以下切實可行的策略事項，以加快注射療法的普及，降低供應鏈風險，並使循證醫學證據的產生與支付模式保持一致。

產業領導者應優先考慮制定整合策略，將臨床證據產生和實際服務提供的投資相結合，以最大限度地擴大患者可及性並實現持續應用。這首先要投資於有針對性的真實世界研究和核准後安全性監測，以解決醫療服務提供者和支付方對特定患者群體（包括兒童和既往接受過治療的患者）的擔憂。產生關於耐受性、抗藥性模式和長期療效的可靠證據，可以顯著增強醫保報銷談判的籌碼，並提升醫療服務提供者的信心。

採用透明的綜合調查方法，結合相關人員訪談、監管審查、臨床文獻綜述和供應鏈情境分析，確保研究結果的嚴謹性。

本研究採用混合方法，結合質性專家訪談、監管文件審查和臨床文獻綜合分析，以全面了解注射型HIV治療藥物。主要研究包括與臨床研究人員、醫院藥局主任、居家醫療計畫主任和供應鏈經理進行結構化訪談，以了解現場操作挑戰和推廣應用的促進因素。此外，還對同行評審文章、臨床試驗報告和監管核准文件進行了有針對性的審查，以確保研究結果與最新的安全性和有效性證據相符。

總之，我們的綜合分析強調了證據綜合、物流和支付方參與之間的合作是推動腸外療法產生廣泛臨床影響的關鍵因素。

注射型HIV治療代表著治療模式的持續轉變，它融合了臨床創新、新型給藥方式以及商業性的複雜性。監管部門的核准、臨床經驗以及日益成長的實際應用表明，只要相關人員能夠解決物流、報銷和供應鏈方面的挑戰，這些治療方法將在特定病患小組中發揮越來越重要的作用。同樣，關稅和採購趨勢也凸顯了營運柔軟性和積極主動的採購決策對於維持治療的可及性和可負擔性的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療方案分類的注射型HIV藥物市場

  • 一線治療
  • 補救性治療
  • 二級治療

9. 按分銷管道分類的注射型愛滋病藥物市場

  • 線上
  • 離線

第10章 以最終用戶分類的注射型愛滋病藥物市場

  • 診所
  • 居家醫療
  • 醫院

11. 依給藥頻率分類的注射型愛滋病藥物市場

  • 每隔一個月
  • 每月一次
  • 季刊

第12章 按年齡層別分類的注射用愛滋病藥物市場

  • 成人版
  • 兒童
  • 老年人

13. 各地區注射用愛滋病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的注射用愛滋病藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國注射用愛滋病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國注射愛滋病藥物市場

第17章：中國的注射用愛滋病藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6A9

The Injectable HIV Medication Market was valued at USD 4.75 billion in 2025 and is projected to grow to USD 5.00 billion in 2026, with a CAGR of 6.75%, reaching USD 7.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.75 billion
Estimated Year [2026] USD 5.00 billion
Forecast Year [2032] USD 7.51 billion
CAGR (%) 6.75%

A concise orientation to how long-acting injectable antiretrovirals are changing clinical practice patterns adherence models and health system logistics

Injectable antiretroviral therapies have matured from clinical curiosities into viable clinical practice options, reshaping therapeutic strategies for people living with HIV. Long-acting formulations offer a fundamentally different adherence profile compared with daily oral regimens, reducing pill burden and offering an alternative pathway for patients who struggle with daily dosing. In parallel, regulatory approvals and real-world evidence accumulation have expanded clinician confidence in injectable regimens, while logistical infrastructures have adapted to accommodate refrigerated storage, administration workflows, and cold-chain distribution considerations.

Clinical adoption is being driven by demonstrable patient-centered benefits including reduced adherence variability and potential improvements in quality of life for selected populations. Health systems are responding by investing in clinic workflows, training nursing staff for intramuscular administration, and integrating electronic health record prompts to manage injection schedules. At the same time, payors and procurement teams are evaluating total cost of care implications as they weigh the clinical advantages against administration cost and distribution complexities. Taken together, these developments mark a substantive inflection point for injectable HIV therapeutics and establish a pragmatic foundation for broader commercialization efforts.

How therapeutic innovation alongside service delivery redesign and logistical investments have collectively redefined adoption pathways for injectable antiretrovirals

The landscape for injectable HIV medication has undergone transformative shifts catalyzed by therapeutic innovation, evolving patient preferences, and shifting delivery paradigms. Novel long-acting integrase inhibitors paired with companion agents have opened clinical pathways that prioritize less frequent dosing and predictable pharmacokinetics. As a result, clinicians are reframing treatment decisions to incorporate regimen convenience and adherence dynamics alongside traditional efficacy and safety endpoints.

Concurrently, distribution and administration models have diversified. Hospital-based infusion centers remain essential for complex patients, but an increasing number of clinics and homecare services are being equipped to administer intramuscular injections, driven by patient demand for decentralized care. This decentralization has required investments in cold chain capacity, staff training, and documentation workflows. Moreover, manufacturers and distributors have adapted commercial strategies to emphasize patient support programs, provider education, and logistical partnerships that reduce friction points between prescription and administration. In sum, the combined effect of therapeutic progress and operational adaptation has redefined how stakeholders approach HIV treatment delivery.

An examination of the 2025 United States tariff adjustments and how heightened import duties are reshaping supply chain, procurement, and pricing decisions

The tariff landscape in the United States for 2025 has introduced new considerations for supply chain managers, procurement leads, and global manufacturers of injectable HIV therapies. Increased import duties can influence landed cost structures for finished injectables and raw materials, necessitating a reassessment of sourcing strategies and inventory management. For organizations operating global supply chains, tariffs amplify the importance of nearshoring, supplier diversification, and contractual protections to mitigate cost volatility.

Operational teams are responding by recalibrating production planning, exploring alternate manufacturing footprints, and negotiating volume-based terms to absorb incremental tariff-induced costs. Regulatory affairs and quality leaders are concurrently evaluating the feasibility of localized fill-and-finish operations to reduce cross-border movement of finished product. Importantly, payors and pricing committees are taking a more granular view of net acquisition costs, administration fees, and service-level obligations as they determine product placement and reimbursement pathways. In this environment, companies that proactively align procurement, manufacturing, and commercial contracting stand to preserve margins and sustain access for patients despite tariff pressures.

In-depth segmentation analysis revealing how age cohorts, treatment line, administration setting, mechanism of action, dosing cadence, and manufacturer dynamics determine clinical and commercial outcomes

Segmentation insights reveal nuanced clinical and commercial dynamics that influence product positioning, service design, and go-to-market strategy. Across age group distinctions, adult and pediatric populations present divergent clinical trial requirements, dosing paradigms, and adherence support needs; pediatric adoption often lags due to formulation and safety considerations, while adult programs focus on broader adherence and long-term tolerability. Treatment line segmentation differentiates first line, salvage, and second line use cases, with first-line positioning emphasizing safety and simplicity, salvage scenarios requiring robust resistance data and tolerability in heavily treated patients, and second-line options balancing efficacy against prior exposure.

Distribution channel choices between hospital pharmacy and retail pharmacy drive different procurement rhythms, administrative responsibilities, and patient access models, as hospital pharmacies typically support complex care pathways while retail pharmacies enable community-based pickup and coordination with clinic administration. Patient type differentiation between treatment experienced and treatment naive cohorts shapes messaging and clinical trial design; treatment experienced patients often require resistance-tailored approaches and monitoring, whereas treatment naive populations prioritize tolerability and initiation convenience. End user context-clinic, homecare, and hospital-dictates administration setting, cold chain demands, and staffing models, with clinic and homecare settings increasingly central to decentralization strategies. Drug mechanism distinctions among integrase inhibitors, NNRTIs, NRTIs, and protease inhibitors inform resistance profiles, combinability, and regimen sequencing decisions. Dosage frequency options of bi-monthly, monthly, and quarterly administration create differentiated adherence profiles and inventory management requirements. Manufacturer dynamics including established biopharmaceutical innovators and diversified generics manufacturers influence pricing strategies, patient support program availability, and distribution partnerships, all of which shape competitive positioning and access pathways.

A comparative regional assessment highlighting how regulatory regimes, reimbursement structures, and healthcare delivery models drive differentiated adoption across major global territories

Regional dynamics vary markedly across the three principal geographies, shaping regulatory pathways, reimbursement environments, and distribution challenges. In the Americas, a mature regulatory infrastructure and well-established HIV care networks accelerate trial uptake and clinician familiarity, while payor negotiations and private-public partnerships drive nuanced formulary placement and access programs. This region often leads in real-world evidence generation and rapid integration of new administration models into clinical practice.

Europe, Middle East & Africa presents a complex tapestry of regulatory regimes, procurement mechanisms, and health system capacities. In parts of Europe, centralized reimbursement frameworks and strong post-market surveillance foster careful but steady adoption, whereas Middle Eastern and African markets reveal heterogeneous infrastructure readiness, variable cold chain capacity, and differing priorities around domestic manufacturing and donor-supported procurement. Asia-Pacific encompasses rapidly evolving demand centers with diverse payer models, from highly centralized procurement systems to market-driven segments. In several Asia-Pacific markets, strong generic manufacturing capabilities and innovative distribution partnerships support alternative commercialization models that can accelerate access when regulatory alignment occurs. Across all regions, local healthcare delivery models, reimbursement policies, and capacity for clinic-based versus home-based administration are decisive factors in determining how injectable therapies are adopted and scaled.

Strategic competitive overview describing how innovation leaders and regional manufacturers deploy formulation, distribution, and partnership strategies to expand injectable therapy access

The competitive landscape for injectable HIV therapies reflects a mix of large integrated pharmaceutical companies and specialized manufacturers focusing on formulation, logistics, and patient support. Leading biopharmaceutical organizations have invested heavily in long-acting formulations, clinical programs, and real-world evidence generation to underpin clinician confidence and payer conversations. These firms typically bring comprehensive patient support solutions, established distribution networks, and access to global regulatory expertise, enabling them to coordinate complex product launches and scale administration programs across multiple care settings.

At the same time, established generic and specialty manufacturers play a growing role by offering alternative pricing models, localized manufacturing, and partnerships that expand distribution reach. Their capabilities in cost-effective production and flexible commercial agreements can facilitate broader patient access, particularly in price-sensitive or procurement-driven environments. Across the competitive set, strategic alliances between originators and local partners, licensing deals that enable regional manufacturing, and investments in distribution infrastructure are common, reflecting a pragmatic approach to accelerating availability while managing commercial and operational risks. Taken together, these company-level dynamics underscore a shift toward collaborative commercialization models as stakeholders seek to balance innovation, affordability, and access.

Actionable strategic priorities for manufacturers, providers, and payors to accelerate access, de-risk supply chains, and align evidence generation with payment models for injectable therapies

Industry leaders should prioritize integrated strategies that align clinical evidence generation with pragmatic service delivery investments to maximize patient access and sustainable uptake. First, invest in targeted real-world studies and post-authorization safety monitoring that address clinician and payor concerns for specific patient cohorts, including pediatric populations and treatment experienced individuals. Generating robust evidence for tolerability, resistance patterns, and long-term outcomes will materially strengthen reimbursement negotiations and provider confidence.

Second, develop flexible distribution and administration models that accommodate clinic-based, homecare, and hospital settings, and design patient support programs that reduce missed appointments and manage storage requirements. Third, mitigate tariff and supply chain risk through diversified manufacturing footprints, nearshoring where feasible, and contractual safeguards with suppliers and distributors to preserve margin and continuity of supply. Fourth, engage payors early with value dossiers that articulate total cost of care implications and address administration fee structures. Finally, pursue collaborative partnerships-licensing, co-commercialization, or strategic alliances-that combine therapeutic innovation with regional manufacturing and distribution expertise to accelerate access while controlling costs. Executed together, these actions will allow organizations to translate clinical innovation into durable, equitable access for patients.

A transparent mixed-methods research design integrating stakeholder interviews, regulatory review, clinical literature synthesis, and supply chain scenario analysis to ensure rigorous findings

The research described here employed a mixed-methods approach combining qualitative expert interviews, regulatory document review, and synthesis of clinical literature to construct a comprehensive understanding of injectable HIV therapies. Primary research included structured conversations with clinical investigators, hospital pharmacy directors, homecare program leads, and supply chain managers to capture frontline operational challenges and adoption drivers. These interviews were complemented by a targeted review of peer-reviewed publications, clinical trial reports, and regulatory approval documents to ensure alignment with the latest safety and efficacy evidence.

Secondary analysis incorporated public filings, patent landscapes, and company disclosures to map manufacturer strategies, distribution partnerships, and manufacturing footprints. Supply chain risk analysis used scenario-based assessments to examine tariff impacts, cold chain requirements, and potential mitigation pathways. Throughout the process, data synthesis emphasized triangulation across sources and explicit documentation of assumptions to support transparency. The methodology prioritized replicability and contextual depth, enabling stakeholders to evaluate strategic levers and operational trade-offs with confidence.

A conclusive synthesis emphasizing coordinated evidence, logistics, and payer engagement as the decisive factors for translating injectable therapies into scalable clinical impact

Injectable HIV therapies represent a durable shift in treatment paradigms that combine clinical innovation with new delivery and commercial complexities. The accumulation of regulatory approvals, clinical experience, and real-world adoption signals that these therapies will occupy an expanding role for selected patient groups, provided stakeholders address logistical, reimbursement, and supply chain challenges. Equally, tariff and procurement dynamics underscore the need for operational flexibility and proactive sourcing decisions to maintain access and affordability.

Successful adoption will hinge on coordinated action across evidence generation, distribution design, and payer engagement. Organizations that invest early in pragmatic clinical data, build versatile administration networks encompassing clinics and homecare, and strategically manage manufacturing footprints will be best positioned to translate therapeutic promise into patient impact. The path forward is collaborative: aligning manufacturers, providers, payors, and service partners around shared outcomes and practical implementation strategies will determine the pace and equity of access to injectable HIV treatments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injectable HIV Medication Market, by Treatment Line

  • 8.1. First Line
  • 8.2. Salvage
  • 8.3. Second Line

9. Injectable HIV Medication Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Injectable HIV Medication Market, by End User

  • 10.1. Clinic
  • 10.2. Homecare
  • 10.3. Hospital

11. Injectable HIV Medication Market, by Dosage Frequency

  • 11.1. Bi Monthly
  • 11.2. Monthly
  • 11.3. Quarterly

12. Injectable HIV Medication Market, by Age Group

  • 12.1. Adult
  • 12.2. Pediatric
  • 12.3. Geriatric

13. Injectable HIV Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Injectable HIV Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Injectable HIV Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Injectable HIV Medication Market

17. China Injectable HIV Medication Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Accord Healthcare Ltd.
  • 18.7. Amneal Pharmaceuticals, Inc.
  • 18.8. Aurobindo Pharma Ltd.
  • 18.9. Boehringer Ingelheim
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Cipla Ltd.
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Genentech, Inc.
  • 18.14. Gilead Sciences, Inc.
  • 18.15. Hetero Labs Limited
  • 18.16. Johnson & Johnson
  • 18.17. Lupin Limited
  • 18.18. Merck & Co., Inc.
  • 18.19. Mylan N.V.
  • 18.20. Sun Pharmaceutical Industries Ltd.
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Theratechnologies Inc.
  • 18.23. Viatris Inc.
  • 18.24. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INJECTABLE HIV MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INJECTABLE HIV MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 128. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)